RMDMEDIUM SIGNALOPPORTUNITY10-K

ResMed delivered solid financial performance with revenue growth of 13.4% and strengthened its market position through the VirtuOx acquisition, expanding its sleep and respiratory care capabilities into home-based diagnostics.

The VirtuOx acquisition represents a strategic expansion into independent diagnostic testing facilities and remote monitoring, positioning ResMed to offer comprehensive end-to-end solutions in sleep and respiratory health. The company's workforce expansion from approximately 10,000 to over 10,600 employees suggests continued investment in growth capabilities, while the acquisition aligns with healthcare's shift toward home-based care delivery models.

Comparing 2025-08-08 vs 2024-08-09View on EDGAR →
FINANCIAL ANALYSIS

ResMed demonstrated strong operational performance with revenue growing 13.4% to $3.0B and gross profit expanding 15.1% to $3.1B, while operating income increased 27.7% to $1.7B. Net income grew notably by 37.2% to $1.4B, supported by a 40.6% reduction in interest expense and improved operational efficiency. The balance sheet strengthened considerably with current assets increasing 48.7% to $3.5B and stockholders' equity rising 22.7% to $6.0B, while operating cash flow grew 25% to $1.8B, reflecting the company's robust cash generation capabilities.

FINANCIAL STATEMENT CHANGES
Current Assets
Balance Sheet
+48.7%
$2.4B→$3.5B

Current assets grew 48.7% — improving short-term liquidity or inventory/receivables build.

Interest Expense
P&L
-40.6%
$40.4M→$24.0M

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Net Income
P&L
+37.2%
$1.0B→$1.4B

Net income grew 37.2% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+27.7%
$1.3B→$1.7B

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Operating Cash Flow
Cash Flow
+25%
$1.4B→$1.8B

Operating cash flow grew 25% — strong conversion of earnings to cash, healthy business fundamentals.

Stockholders Equity
Balance Sheet
+22.7%
$4.9B→$6.0B

Equity base grew 22.7% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Total Assets
Balance Sheet
+18.9%
$6.9B→$8.2B

Asset base grew 18.9% — expansion through organic growth, acquisitions, or capital deployment.

Gross Profit
P&L
+15.1%
$2.7B→$3.1B

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Revenue
P&L
+13.4%
$2.6B→$3.0B

Revenue growing 13.4% — solid top-line momentum, watch margins for quality of growth.

Inventory
Balance Sheet
+12.8%
$822.3M→$927.7M

Inventory built 12.8% — monitor whether demand supports this build or if write-downs may follow.

LANGUAGE CHANGES
NEW — 2025-08-08
PRIOR — 2024-08-09
ADDED
At August 4, 2025, the registrant had 146,414,839 shares of Common Stock, $0.004 par value, issued and outstanding.
This number excludes 43,925,747 shares held by the registrant as treasury shares.
We also provide management software that assists durable or home medical equipment (DME/HME) providers, and other long-term care providers operate more effectively and efficiently across various residential care settings.
In May 2025, we acquired VirtuOx, a software-enabled independent diagnostic testing facility, or IDTF, and provider of technology solutions to facilitate in-home and remote testing services for sleep, respiratory, cardiac, and other health conditions across the United States, or U.S.
This acquisition strengthens our position in the sleep and breathing health market by expanding our ability to offer end-to-end solutions, including home-based diagnostics and patient monitoring.
+7 more — sign up free →
REMOVED
At August 5, 2024, the registrant had 146,932,119 shares of Common Stock, $0.004 par value, issued and outstanding.
This number excludes 42,664,067 shares held by the registrant as treasury shares.
We also provide management software to agencies providing OOH care, including but not limited to home medical equipment, or HME, home health and hospice, skilled nursing, life plan community, senior living, outpatient therapy and private duty services.
AND SUBSIDIARIES We employ over 9,980 people and sell our products in over 140 countries through a combination of wholly owned subsidiaries and independent distributors.
Segment Information We operate in two segments, which are the Sleep and Respiratory Care segment and the Software as a Service, or SaaS, segment.
+7 more — sign up free →
MORE OPPORTUNITY SIGNALS
ABTHIGHAbbott announced a major strategic acquisition of Exact Sciences Corporation to ...
2026-02-20
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →